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TO THE EDITOR
A 51-year-old Japanese man with nasal bleeding was examined at our hospital for pancytopenia in July 1998. His peripheral WBC was 2.0 × 10 9 /l with 37.0% neutrophils. The concentration of hemoglobin and the platelet count were 8.6 g/dl and 15 × 10 9 /l, respectively. His bone marrow smear showed that the number of nucleated cells was 245 × 10 9 /l and M/E ratio was 0.55. Myeloblasts occupied 31.6% of the nonerythroid nuclear cells in the smear. On the basis of these clinical data, he was diagnosed with acute myelogenous leukemia (M6), and induction chemotherapy was carried out with idarubicin (13 mg/m 2 , days 1-3) and Ara-C (100 mg/m 2 by continuous i.v. infusion, day 1-7). During the treatment, the patient exhibited febrile neutropenia. All cultures from his blood, throat, urine and stool were negative. However, his serum ␤-D-glucan level was elevated at 188.0 pg/ml (normal Ͻ20 pg/ml).
67
Ga scintillation scan did not reveal any focus of inflammation and no Pneumocystis carinii DNA was detected using polymerase chain reaction (PCR). Therefore, a fungal pathogen was highly suspected, and amphotericin B (AMPH) was initiated at 50 mg/day. The dose of AMPH was gradually increased to 150 mg/day due to the lack of response, and although 150 mg/day of AMPH was administered for 25 days, his high fever continued and the serum value of ␤-D-glucan remained elevated (100-120 pg/ml). The total dose of administered AMPH reached to 6600 mg. Since an uncontrolled mycotic infection was suspected, a high dose of itraconazole (ITCZ) per os, initially 500 mg/day followed by 700 mg/day, was administered and serum level of ␤-D-glucan decreased (25-45 pg/ml). The patient's high fever was lowered. It was considered that high dose of ITCZ was effective in this patient.
In December 1998, the patient complained of gradually increasing lower back pain without neurologic deficit. Magnetic resonance imaging (MRI) scanning of the lumbar spine showed spondylodiscitis at the L1/2 spinal level. The needle biopsy specimens of the intervertebral disc revealed Aspergillus sp. (Figure 1 ). Although the administration of 50 mg/day of AMPH and 200 mg/day of ITCZ were started, the serum level of ␤-D-glucan also gradually elevated again (59.5 pg/ml). Renal dysfunction due to toxicity of AMPH was progressive (serum creatinine level was 2.2 mg/dl). Therefore, we administered a high dose of ITCZ (900 mg/day) instead of AMPH for 21 days after the patient gave informed consent. During the high-dose ITCZ therapy, the concentrations of ITCZ and hydroxy-ITCZ, its active metabolite, in blood was elevated to 5924 ng/ml (day 19) and 13 000 ng/ml (day 26), respectively (Figure 2 
Figure 1
Needle biopsy specimens of the intervertebral disc (L1/2) revealed to be involved by Aspergillus sp.
Figure 2
Blood concentration of itraconazole (ITCZ) and hydroxyitraconazole (ITCZ-OH).
tration were achieved without any significant side-effects. Serum level of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were within the normal range during 900 mg/day ITCZ administration. The patient's fever and low back pain decreased and the serum ␤-D-glucan level became normal. Thus, from these results, we suggest that the oral administration of ITCZ at a high dose is clinically useful to treat a case of Aspergillus spondylodiscitis.
Aspergillus spondylodiscitis is one of the rare complications of the deep mycotic infections. 1 In cases of hematological disorder, surgical debridement of the fungus abscess on the lumbar disc is usually not indicated because of the patient's poor systemic condition due to malignant disease. Although AMPH has been predominantly used as the first choice of drug for such patients, 2 it has been reported that intravenous AMPH therapy has a low success rate (34%) against invasive aspergillosis. 3 Moreover, if the patient does not respond to a high dose of AMPH, or if the side-effects are severe, it is difficult to exchange AMPH for other drugs. In the present case, the administration of a high dose of ITCZ was effective without any serious sideeffects. Glasmacher et al 4 reported that a trough concentration of at
Detection of myeloperoxidase by flow cytometry in acute lymphoblastic leukaemias with BCR-ABL gene rearrangement
TO THE EDITOR Myeloperoxidase (MPO) is an enzyme found exclusively in the primary granules of myeloid cells. Thus, according to the French-American-British classification, leukaemias with MPO activity in Ͼ3% of blasts are classified as acute myeloid leukaemias (AML). However, acute lymphoblastic leukaemias (ALL) can express one or more surface myeloid antigens (usually CD13, CD33 or CD66) and recently, we and others have demonstrated that ALL can also display MPO gene expression at mRNA level in the absence of MPO activity, specially in those cases with BCR-ABL or MLL genes rearrangements.
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In a recent paper published in Leukemia, Tabernero et al 3 identified a unique immunophenotype expressed by adult precursor B lineage acute lymphoblastic leukaemia with BCR-ABL rearrangement. This finding is based on the analysis of surface antigens, such as the homogeneous expression of CD10 and CD34, heterogeneous or low expression of CD38 and aberrant CD13. In our experience, we have also found that BCR-ABL-positive ALL, can also display cytoplasmic Leukemia least 500 ng/ml ITCZ was necessary for an effective antifungal prophylaxis in neutropenic patients and they compared the results of drug monitoring in patients with acute leukemia receiving six different dosing regimens using ITCZ capsules and hydroxypropyl-␤-cyclodexytrin solution in their clinical study. They concluded that the maximum dosing group, 400 mg/day ITCZ solution with a loading dose of 800 mg/day capsules for 7 days resulted in sufficient trough concentrations for significant antifungal prophylaxis in neutropenic patients. To our knowledge, this is the first reported case of ITCZ therapy administered at such a high dose as 900 mg/day as capsules only, without complications. Though future studies are needed to elucidate the efficacy and toxicity of high-dose ITCZ therapy, it could be the appropriate substitute of AMPH-resistant invasive aspergillosis. 
